MBX Capital is on record against 30 companies.
We invest at early stages, writing $1–2.5M first checks for ≥5% equity. Our focus is deep-health systems spanning biology, chemistry, AI/ML, robotics, and clinical medicine. Geographically, we leverage a private expert network for global deal sourcing and vetting.